Ann Stuart
Family Medicine · Knoxville, TNNPI 1699873554
Payments from drug & device makers
Across 521 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$727
- Lilly USA, LLC$656
- Pfizer$513
- AstraZeneca$478
- Boehringer Ingelheim$478
- plus $4K from 29 others
What the payments were for
- Food & beverage$7,66998%
- Education$1242%
- Gifts$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 68 | $1,014 |
| AbbVie(2 entities) | 61 | $727 |
| Lilly USA, LLC | 41 | $656 |
| Pfizer | 35 | $513 |
| AstraZeneca(2 entities) | 33 | $478 |
| Boehringer Ingelheim | 33 | $478 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $403 |
| GSK | 28 | $403 |
| Amarin Pharma, Inc. | 27 | $399 |
| Sanofi-aventis U.S. LLC | 16 | $251 |
| E.r. Squibb & Sons, L.L.C. | 15 | $245 |
| Bayer | 15 | $205 |
| Antares Pharma, Inc. | 13 | $186 |
| Astellas Pharma US Inc | 4 | $171 |
| Merck | 11 | $170 |
| Amgen | 12 | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $168 |
| Novartis | 9 | $167 |
| Arbor Pharmaceuticals, Inc. | 10 | $159 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $147 |
| Eisai Inc. | 8 | $123 |
| Johnson & Johnson | 7 | $104 |
| Mylan Specialty L.p. | 5 | $82 |
| Xeris Pharmaceuticals, Inc. | 4 | $73 |
| Ultragenyx Pharmaceutical Inc. | 2 | $48 |
| Biohaven Pharmaceuticals, Inc. | 3 | $46 |
| Clarus Therapeutics Inc. | 3 | $46 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Genentech USA, Inc. | 1 | $25 |
| Ascend Therapeutics US, LLC | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Halozyme Inc | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
How this compares
$7,811 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $9,244 |
| Rosuvastatin Calcium | 18 | $232 |
| Levothyroxine Sodium | 28 | $209 |
| Omeprazole | 13 | $175 |
| Atorvastatin Calcium | 14 | $127 |
| Losartan Potassium | 12 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $513 | $9,24414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Knoxville
- Rickey ManningKnoxville$8.1M
- Paul WakefieldKnoxville$4.3M
- Jerry PunchKnoxville$2.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Emily HubbsKingsport$2.8M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.